Research
Hormonal
Once-weekly semaglutide (2.4 mg) significantly improves health-related quality of life and reduces body weight in obese patients with HFpEF.
If you are obese and have HFpEF, ask your doctor about semaglutide (Ozempic/Wegovy). The STEP-HFpEF trial showed that taking 2.4 mg once weekly significantly improved quality of life and reduced body weight by over 13% compared to placebo.
GoodSupportsHIGH confidence
The STEP-HFpEF trial... enrolled 529 symptomatic, physically limited obese HFpEF patients who were randomized 1:1 to receive either placebo or once-weekly semaglutide 2.4 mg. At 52 weeks, semaglutide treatment resulted in a mean improvement of 16.6 points in the KCCQ-CSS... Additionally, compared with the placebo, semaglutide induced a 13.3% reduction in body weight.
Why this rating
Based on a single, dedicated RCT (STEP-HFpEF) with 529 patients.
Source
Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
Wenwen Zheng et al. · Diabetology & Metabolic Syndrome · 2025
DOI 10.1186/s13098-025-01917-z
narrative_reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sodium glucose cotransporter 2 inhibitors (SGLT2i) significantly reduce the composite risk of cardiovascular death or heart failure hospitalization in patients with heart failure with preserved ejection fraction (HFpEF), regardless of diabetes status.Strong
- Exercise training (ET), including high-intensity interval training (HIIT) and moderate-intensity continuous training, improves functional status, exercise capacity, and quality of life in HFpEF patients.Good
- Lifestyle interventions, including dietary management (DASH/SDR, Low-Energy Diet) and exercise training, improve clinical outcomes in obese HFpEF patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →